Genome Publications
https://doi.org/10.61096/ 978-81-981372-8-9_16

Chapter 16

Innovative Drug Delivery Systems For Herbal Hepatoprotective Agents: Advances And Future Directions

Dr. Kiran Gerapati
Associate Professor, Department of Pharmacology, A.M Reddy Memorial College of Pharmacy, Petlurivaripalem, Narasaropet, Palnadu dist, Andhra Pradesh,
Dr. Y.Ratna Sindhu
Professor and HOD, department of Pharmaceutical regulatory affairs, Chennupati Indo-American School of Pharmacy, Jonnalagadda, Narasraopet.
Ramalingeswara Rao Kasula
Assistant Professor, Department of Pharmaceutical Chemistry, SIR C.R Reddy College of Pharmaceutical Sciences
Vinjavarapu L.Anusha
Associate Professor, Department of Pharmacology, SIMS College of Pharmacy, Guntur.

Abstract: The growing prevalence of liver diseases has intensified the search for more effective hepatoprotective therapies. While herbal medicines have demonstrated hepatoprotective properties, their therapeutic potential is often limited by poor bioavailability, rapid metabolism, and low aqueous solubility. Recent advancements in innovative drug delivery systems offer promising solutions to enhance the efficacy of herbal hepatoprotective agents. This chapter explores cutting-edge approaches, including liposomes, phytosomes, polymeric nanoparticles, nanoemulsions, solid lipid nanoparticles, and hydrogels, which improve the absorption, stability, and targeted delivery of bioactive compounds such as silymarin, curcumin, and glycyrrhizin. These technologies optimize pharmacokinetics, reduce systemic toxicity, and enhance therapeutic outcomes by ensuring sustained release and hepatocyte-targeted action. Additionally, regulatory challenges, safety considerations, and future prospects of nanotechnology-driven herbal hepatoprotective formulations are discussed. Integrating advanced drug delivery strategies with traditional herbal medicine has the potential to revolutionize liver disease treatment, paving the way for more effective and sustainable hepatoprotective therapies.

Keywords: Hepatoprotection, herbal medicine, innovative drug delivery, nanotechnology, liposomes, phytosomes, polymeric nanoparticles, nanoemulsions, solid lipid nanoparticles, curcumin, silymarin, liver diseases, targeted therapy, bioavailability enhancement.

Citation: Kiran Gerapati, Y.Ratna Sindhu, Ramalingeswara Rao Kasula, Vinjavarapu L.Anusha. Innovative Drug Delivery Systems For Herbal Hepatoprotective Agents: Advances And Future Directions. *Advancements in Hepatoprotective Herbal Medicines Current Trends, Significance, and Future Perspectives.* Genome Publications. 2025; Pp211-220. https://doi.org/10.61096/978-81-981372-8-9_16

INTRODUCTION

The global burden of liver diseases has intensified the quest for effective treatments that can safeguard hepatocytes against a vast array of insults. Viral infections, metabolic imbalances, autoimmune reactions, and harmful substances all conspire to damage hepatic cells, impair detoxification processes, and disrupt metabolic homeostasis [1]. Despite the availability of several synthetic drugs, adverse effects and high costs often limit their long-term use, prompting researchers and clinicians to seek safer, more sustainable solutions. Traditional herbal approaches occupy a central place in this endeavor, offering centuries of empirical wisdom blended with modern scientific exploration. Yet, conventional delivery methods for plant-based remedies face significant shortcomings: limited aqueous solubility, erratic bioavailability, and difficulties in ensuring targeted release. One might wonder how we can harness the full potential of herbal medications in a clinical setting. Recent advances in drug delivery technology suggest that novel carriers, nano-formulations, and specialized vehicles can transform plant-derived molecules into potent, site-specific therapeutics for hepatic disorders. In this chapter, key principles of herbal hepatoprotective therapy are revisited, followed by a critical appraisal of current challenges. The narrative then shifts to innovative drug delivery systems that promise to boost therapeutic outcomes. Throughout the discussion, questions surrounding clinical validation, regulatory nuances, and future prospects take center stage. Indeed, the shift toward sophisticated formulation technologies may represent a paradigm shift, not only for liver-related disorders but for broader fields of herbal medicine.

Liver Diseases and the Imperative for Effective Hepatoprotection

Hepatic disorders remain a leading cause of morbidity and mortality worldwide, spanning nonalcoholic fatty liver disease, viral hepatitis, alcoholic liver injury, drug-induced toxicity, and hepatocellular carcinoma [2]. The liver's central role in detoxification, protein synthesis, and metabolic regulation renders it highly susceptible to damage from multiple environmental, pathogenic, and iatrogenic factors. While conventional pharmaceuticals such as interferons, direct-acting antivirals, and specific enzyme inhibitors offer significant relief in many conditions, their side effects or limited efficacy often underscore the need for alternative therapies [3]. Herbal remedies have consistently drawn attention for their prophylactic and therapeutic roles in hepatic ailments. One classic example is Silybum marianum (milk thistle), traditionally employed for alcohol-related liver damage and toxin-induced hepatocellular injury [4]. Studies have suggested that its main active constituent, silymarin, confers antioxidant and cytoprotective benefits. Similarly, Curcuma longa (turmeric) and its principal component, curcumin, have gained traction for modulating inflammatory cascades and oxidative stress [5]. Nonetheless, many of these phytochemicals exhibit suboptimal clinical outcomes when delivered as crude preparations. What if these compounds could reach the liver in a sustained, targeted manner, amplifying their intrinsic strengths while minimizing systemic exposure? The subsequent sections delve into precisely how modern drug delivery systems attempt to address this question.

Traditional Herbal Medicines in Liver Therapy

Well before contemporary pharmacology emerged, numerous cultures championed the use of botanicals to counteract hepatic ailments. Ancient Ayurvedic texts describe formulations containing Phyllanthus amarus, Boerhavia diffusa, and Picrorhiza kurroa, while Traditional Chinese Medicine (TCM) frequently employs Glycyrrhiza glabra (licorice root), Schisandra chinensis, and Gardenia jasminoides to improve liver function [6]. Similar patterns can be observed in Middle Eastern, African,

and Native American traditions. These approaches typically revolve around polyherbal concoctions believed to leverage synergistic interactions among distinct phytochemicals. Indeed, this synergy often presents a unique advantage over single-compound strategies. Still, the precise interactions between co-occurring molecules remain elusive, complicating standardization and dose optimization. For instance, a multi-herb decoction may contain dozens of minor bioactive constituents, each influencing absorption and metabolism in unpredictable ways [7]. Efforts to modernize these therapies have thus emphasized the extraction and quantification of specific marker compounds (e.g., silybin in milk thistle), followed by rigorous clinical trials. Yet, such steps, while essential, do not always guarantee reproducible efficacy when confronted by formidable pharmacokinetic barriers. It is within this landscape of complex chemical profiles and intricate physiological barriers that novel carriers and formulation strategies truly shine.

Limitations of Conventional Herbal Delivery

It remains an unfortunate reality that many promising phytochemicals do not reach their full therapeutic potential, primarily due to poor oral bioavailability and ineffective organ targeting. A range of natural compounds that display potent in vitro hepatoprotective properties fail to elicit similar responses in clinical contexts. The reasons often revolve around a few recurring constraints. First, phytochemicals like curcumin, silymarin, and quercetin have limited aqueous solubility, curtailing their absorption in the gastrointestinal tract [8]. Upon ingestion, these molecules can undergo extensive first-pass metabolism, rapidly losing efficacy. Second, changes in gut microbial composition and pH levels also alter the fate of active ingredients. Certain individuals may metabolize these compounds more quickly, which introduces variability in therapeutic outcomes. Finally, delivering consistent, standardized dosages remains challenging due to variations in cultivation, harvest, and storage. Even when high-quality extracts are available, ensuring that active molecules accumulate in liver tissue in therapeutic concentrations is far from straightforward. These problems have provoked a re-evaluation of how we present herbal agents to the body. Might cutting-edge technologies that encapsulate or bind these fragile molecules in protective matrices offer a game-changing leap in efficacy? Indeed, nanocarriers, vesicular systems, and polymeric scaffolds promise to circumvent classical barriers and bring these compounds precisely where they are needed.

Innovative Delivery Systems

Significant interest has emerged in the intersection of advanced drug delivery science and herbal medicine, as researchers adapt methods originally developed for synthetic pharmaceuticals to plant-derived compounds. This shift has led to the creation of platforms that improve solubility, protect against degradation, and offer controlled release profiles. While each technology has its strengths and limitations, the collective evolution represents an exciting frontier in pharmaceutics.

Liposomal and Phytosomal Formulations

Liposomes, typically constructed from phospholipid bilayers surrounding aqueous cores, have been used extensively since the 1970s for delivering anticancer drugs and vaccines [9]. Encapsulation in liposomes shields phytochemicals from harsh gastric conditions, enzymes, and oxidative degradation. In the context of hepatoprotection, this approach can be particularly advantageous if the liposome surface is functionalized with ligands that bind to hepatocyte receptors. The presence of galactose residues, for instance, can target the asialoglycoprotein receptor, a hallmark of hepatic cells [10]. Phytosomes, although structurally akin to liposomes, result from a specific complexation between phospholipids and the herbal extract itself. These complexes align in a manner that might

enhance molecular stability and lipid solubility [11]. Silybin-phosphatidylcholine complexes have shown greater bioavailability and superior hepatic outcomes than conventional silymarin preparations in numerous clinical studies [12]. The phenomenon emerges partly from increased membrane permeability; the phytosome enters cells more easily, thus elevating local concentration at the therapeutic site.

Polymeric Nanoparticles

Solid colloidal structures formed from biodegradable polymers such as chitosan, alginate, or poly(lactic-co-glycolic acid) (PLGA) create a robust environment to encapsulate a range of bioactives. Polymeric nanoparticles confer both protection and controlled release, mitigating the enzymatic degradation that typically besets free phytochemicals [13]. Through careful tuning of particle size, surface charge, and polymer composition, researchers can manipulate release kinetics and uptake pathways. Some investigators have incorporated curcumin or andrographolide into polymeric nanoparticles, thereby extending circulation times and improving hepatic targeting [14]. This shift suggests that patient outcomes might improve with fewer doses and a more sustained effect.

Metallic Nanoparticles and Nanoemulsions

Metallic nanoparticles often silver, gold, or iron oxide have also garnered attention for their capacity to attach to and transport phytochemicals [15]. Although some safety concerns persist regarding potential toxicity and long-term accumulation, preliminary studies hint at improved cellular uptake and minimal oxidation of labile herbal constituents. The surface of metallic nanoparticles can likewise be modified with polymers or antibodies to enhance selectivity toward hepatocytes. Nanoemulsions, in contrast, rely on ultra-fine emulsified droplets, often stabilized by surfactants or co-surfactants. These droplets enlarge the contact surface area between the drug and the gastrointestinal lumen, thereby promoting absorption. When silymarin is incorporated into a nanoemulsion, for instance, it can show faster absorption and higher plasma levels compared to conventional formulations [16]. Yet achieving stability in these emulsions can be problematic, necessitating extensive optimization of the emulsifier system.

Solid Lipid Nanoparticles (SLNs) and Nanostructured Lipid Carriers (NLCs)

Solid lipid nanoparticles, formed from solid lipids stabilized by surfactants, have emerged as another significant innovation, blending the benefits of polymeric carriers and lipid-based vesicles. By entrapping herbal compounds in a lipid matrix, one may preserve their integrity and facilitate slow release [17]. Some research groups have experimented with silymarin- or curcumin-loaded SLNs in chronic liver disease models, noting improved pharmacokinetic profiles and reduced hepatic oxidative stress markers [18]. Nanostructured lipid carriers upgrade SLNs by incorporating oils within the solid lipid framework. This design aims to reduce imperfections in the lipid structure, thereby enabling higher loading capacities. In animal studies, NLCs containing glycyrrhizin have shown promise for reversing certain inflammatory processes. One might regard these findings as early but pivotal evidence that lipid-based nanocarriers could revolutionize standard herbal treatments for liver conditions.

Hydrogels and Mucoadhesive Systems

Hydrogels present another avenue for controlled drug release. These water-swollen networks can encapsulate phytochemicals and gradually liberate them in response to physiological stimuli, such as changes in pH or enzymatic activity [19]. Mucoadhesive formulations, designed to

adhere to the gastrointestinal mucosa, prolong the contact time of the drug with absorption sites. This phenomenon may boost bioavailability further, particularly for compounds with limited stability in luminal fluids. Hydrogels are often fabricated from natural polymers like alginate, pectin, or chitosan, which allows synergy with the herbal extract's inherent properties. This approach holds potential in conditions that require consistent blood levels of active agents over prolonged periods, such as chronic hepatitis or cirrhosis. Observers might argue that this approach, though still nascent, illustrates a clear trajectory in modern pharmaceutics: harnessing biocompatible materials to transform the fate of delicate bioactive molecules.

Mechanisms of Action and Pharmacokinetic Considerations

Innovative delivery systems do not merely solve physical or chemical limitations; they also modulate key pharmacokinetic parameters, ultimately enhancing therapeutic potential. A deeper look at how these technologies influence absorption, distribution, metabolism, and excretion (ADME) offers insight into their clinical promise.

Enhanced Solubility and Protection Against Degradation

Nanocarriers and lipid-based vesicles serve as protective cocoons, isolating phytochemicals from unfavorable gastric pH and enzymatic activity [20]. This can be likened to encasing a fragile piece of art in a robust container to ensure it remains intact until it reaches its exhibition site. The carrier's shell also prevents oxidation, a common threat for phenolic or flavonoid compounds. This protection against degradation is vital for molecules that degrade readily in neutral or alkaline environments, a scenario frequently encountered in the intestinal tract.

Improved Tissue Uptake and Targeting

In conditions involving fibrotic or cirrhotic livers, normal blood flow pathways can be disrupted, making it harder for free drugs to navigate. Advanced formulations circumvent these obstacles. Liposomes, particularly when they bear targeting moieties, can interact specifically with hepatocytes or hepatic stellate cells. Alternatively, positively charged nanoparticles may exploit electrostatic attractions to accumulate in damaged tissues that exhibit altered vascular permeability [21]. This phenomenon also depends on the concept of the enhanced permeability and retention effect. Though most often discussed in oncology, certain types of inflamed or fibrotic tissues can exhibit a degree of abnormal vascularity that facilitates nanoparticle uptake. Thus, even passive targeting when no specific ligand is attached can improve drug retention in diseased liver regions [22].

Modulating Biodistribution and Metabolism

By restraining systemic exposure, advanced systems reduce the quantity of phytochemicals that undergo hepatic first-pass metabolism or renal clearance before exerting therapeutic effects [23]. Encapsulation can effectively camouflage the molecule from metabolic enzymes. Similarly, slow-release profiles help maintain steady plasma levels, reducing the likelihood of peak-trough fluctuations that may exacerbate adverse reactions or compromise efficacy. Recent studies involving polymeric micelles loaded with andrographolide demonstrate how altering biodistribution can magnify anti-inflammatory and antifibrotic outcomes [24]. Instead of a quick burst of release followed by an equally fast decline, the micelles release andrographolide gradually, sustaining meaningful plasma and tissue concentrations. One might view this as a carefully curated performance, where the star of the show appears on stage just at the right intervals to maximize impact without overstaying its welcome.

Clinical and Preclinical Evidence

While theoretical and mechanistic discussions illuminate the potential of advanced herbal formulations, their true measure lies in empirical outcomes. A surge in both animal experiments and early human trials underscores the transformative potential of these cutting-edge systems. Yet challenges persist in translating encouraging laboratory data into widespread clinical practice.

Notable Preclinical Investigations

Numerous rodent and in vitro experiments have spotlighted the heightened efficacy of nano-delivered herbal compounds. For instance, rats with carbon tetrachloride–induced liver injury exhibited dramatic improvements in liver function tests and histopathological markers after receiving nanoencapsulated silymarin, compared to traditional silymarin [25]. Investigators noted that hepatic collagen deposition and inflammatory cytokines showed a marked reduction, suggesting that the nanoformulation successfully mitigated fibrotic progression. Similarly, curcumin-laden liposomes have reduced oxidative stress and modulated pro-inflammatory signals more effectively in ischemia-reperfusion injury models than free curcumin [26]. Researchers hypothesize that this enhanced protection arose from superior cellular internalization of the encapsulated compound, underscoring how optimized formulations can shift a known agent's efficacy from moderate to robust.

Emerging Clinical Trials

Although large-scale human studies remain limited, smaller-scale trials offer encouraging glimpses of progress. One pilot study exploring nano-sized silymarin in alcoholic fatty liver disease showed statistically significant decreases in serum alanine aminotransferase (ALT) levels after three months, which contrasted with modest changes in the group receiving standard silymarin capsules [27]. Patient-reported quality-of-life scores likewise improved, raising hopes that nano-delivery could provide genuine clinical benefits. Curcumin phytosomes also have undergone clinical assessment for nonalcoholic steatohepatitis (NASH), revealing improvements in liver ultrasound findings and serum markers of oxidative stress [28]. These preliminary findings point toward broader potential, prompting discussions about refining delivery vehicles, optimizing dosing schedules, and conducting more robust randomized trials.

Synergistic Possibilities

In some explorations, herbal extracts are paired with conventional pharmaceuticals to exploit complementary mechanisms. Combining nano-liposomal glycyrrhizin with standard antiviral therapy for chronic hepatitis B, for example, has been investigated for synergistic modulation of inflammation and viral load [29]. Such integrated regimens could enable reduced reliance on high doses of synthetic drugs, thereby lessening side effects and financial costs. It remains essential to confirm the compatibility of each agent, as well as the stability of the overall formulation, but these early efforts highlight the versatility of advanced drug delivery systems.

Regulatory and Safety Considerations

New technologies, though undeniably promising, also raise questions about safety, quality control, and regulatory compliance. Herbs are not automatically benign, and nanoformulated herbal products demand scrutiny akin to that of novel synthetic entities.

Quality Control and Standardization

One core challenge stems from natural variability in raw plant materials. Soil conditions, harvesting times, and extraction processes can all alter phytochemical profiles [30]. Manufacturers who wish to commercialize advanced herbal formulations must ensure consistent marker compounds across batches. Regulators typically demand rigorous characterization of the nanoparticle size, surface morphology, encapsulation efficiency, and residual solvents. Analytical methods such as high-performance liquid chromatography (HPLC) or mass spectrometry-based assays verify both the identity and purity of the active ingredient [31]. This standardization is particularly imperative for multi-ingredient herbal formulations, where subtle changes in ratio might affect overall therapeutic outcomes. Developers may employ fingerprinting methods to capture the entire phytochemical profile, although regulatory frameworks differ substantially by region.

Nanotoxicology and Long-Term Safety

Nanoparticles introduce a unique set of safety considerations. They may accumulate in non-target organs or trigger immune reactions, especially if their size, surface charge, or composition predisposes them to opsonization [32]. Thorough investigations spanning acute toxicity to chronic exposure studies must be performed to rule out cumulative risks. Even biodegradable carriers like PLGA can generate byproducts that require scrutiny, particularly in long-duration treatments where Repeated dosing is inevitable [33]. Long-term follow-up in clinical trials is likewise prudent, as the consequences of extended nanoparticle circulation remain incompletely understood. Although many systems have shown favorable safety in short-term studies, comprehensive assessments remain critical for broad adoption. The field of nanotoxicology continues to evolve, producing more refined protocols for evaluating novel carriers.

Navigating Regulatory Frameworks

Regulatory agencies such as the United States Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have distinct pathways for botanical drugs, dietary supplements, and conventional pharmaceuticals. The introduction of nanotechnology complicates this further, as formulations may fall into overlapping categories [34]. Sponsors might face additional hurdles proving bioequivalence if the reference product is a complex botanical extract. These hurdles reinforce the necessity for robust, multi-phase clinical trials that incorporate well-defined endpoints. The shift toward advanced carriers also draws attention to labeling and post-marketing surveillance, ensuring that any adverse events linked to the technology are detected early. Despite these obstacles, a growing number of investigational new drug (IND) filings for nanoformulated botanicals suggests that the landscape is gradually adapting.

Future Prospects

As scientific inquiry deepens, the horizon of herbal hepatoprotection expands in ways that blend multidisciplinary expertise and emerging technologies. Interrogations of how advanced carriers could align with personalized medicine, computational modeling, and greener manufacturing strategies set the stage for an exciting era.

Personalized Herbal Medicine and Precision Formulation

Patients vary enormously in genetic makeup, microbiota composition, and environmental exposures, each potentially influencing how they metabolize or respond to herbal compounds. The future may involve personalized nanoparticle formulations tailored to an individual's enzymatic profile

or disease progression stage to maximize efficacy and minimize adverse effects [35]. One can envision a scenario where clinicians use pharmacogenetic data to design an optimized curcumin nano-liposomal blend for patients carrying specific polymorphisms affecting hepatic uptake or metabolism. This level of customization, while technically challenging, aligns with broader trends in precision medicine.

Computational Modeling and Artificial Intelligence

Machine learning and computational simulations hold enormous potential for accelerating the design of novel delivery systems. AI-driven algorithms could screen thousands of potential combinations of lipids, surfactants, or polymers to predict which formulations will achieve desired parameters for size, stability, and release kinetics [36]. Researchers may reduce the iterative process of trial-and-error, speeding the path to clinical translation. Such integrative approaches could also assist in toxicity prediction, spotlighting nanoparticle designs at heightened risk for unwanted interactions. This synergy between informatics and wet-lab experimentation might become a defining feature of twenty-first-century pharmaceutical development, equally applicable to herbal and synthetic agents.

Green Manufacturing and Sustainability

Growing environmental awareness prompts calls for eco-friendly production methods in the pharmaceutical sector. Botanical extracts and natural polymers already resonate with this ethos, yet the solvents, surfactants, and stabilizers sometimes employed in nanotechnology can be less benign. Researchers are now exploring greener emulsification techniques, solvent-free particle synthesis, or biodegradable packaging materials for large-scale manufacturing [37]. This push toward sustainability may also enhance public acceptance of herbal nanomedicines, especially if the entire supply chain, from cultivation to packaging, aligns with environmentally responsible practices.

Expanding Application Domains

Although the current focus rests firmly on the liver, advanced herbal formulations could be adapted to address other complex disorders. Similar strategies might benefit conditions such as renal fibrosis, neurodegeneration, or chronic inflammatory pathologies, where targeted delivery can amplify the therapeutic index of phytochemicals [38]. Such expansions hinge on continuing success stories in the hepatic realm, positioning the liver as a proving ground for the broader renaissance of plant-based nanomedicine.

CONCLUSION

In the unfolding narrative of liver health, herbal remedies stand at a fascinating crossroads. The inherent strengths of traditional phytomedicines multifaceted bioactivity, historical usage, and relative safety now intersect with sophisticated drug delivery systems that promise to address the age-old conundrums of solubility, stability, and targeted therapeutic action. From liposomal silymarin to polymeric curcumin nanoparticles, researchers are leveraging advanced technologies to transform once-underperforming botanical molecules into potent hepatoprotective agents. Nevertheless, key questions remain. Will higher production costs and specialized expertise limit access, thereby preventing these innovations from reaching those who might benefit the most? Can regulatory bodies evolve quickly enough to fairly evaluate and approve complex botanical-nano hybrids without stifling innovation? The path ahead is neither simple nor guaranteed, yet the potential rewards reduced liver disease burden, safer long-term therapy, and novel paradigms in precision medicine are profoundly

motivating. By weaving traditional knowledge with cutting-edge engineering, a future where herbal therapies firmly stand alongside, or even eclipse, conventional modalities is imaginable. This chapter has illuminated the challenges, triumphs, and prospective frontiers in this domain. As research advances and clinical insights deepen, one can hope that these innovative drug delivery strategies will catalyze a new wave of effective, patient-centered treatments for a wide range of hepatic conditions.

REFERENCES

[1] Asrani SK, etal., Burden of liver diseases in the world. J Hepatol. 2019;70(1):151–171.
[2] Setiawan VW, Stram DO, Porcel J, Lu SC, Le Marchand L, Noureddin M. Non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH): An overview and future perspectives. Nat Rev Gastroenterol Hepatol. 2022;19(6):411–424.
[3] Schuppan D, Afdhal NH. Liver cirrhosis. Lancet. 2008;371(9615):838–851.
[4] Abenavoli L, Capasso R, Milic N, Capasso F. Milk thistle in liver diseases: past, present, future. Phytother Res. 2010;24(10):1423–1432.
[5] Aggarwal BB, Surh YJ, Shishodia S. The molecular targets and therapeutic uses of curcumin in health and disease. Adv Exp Med Biol. 2007;595:1–75.
[6] Xiang B, etal., Traditional Chinese Medicine as a treasure trove for new drug discovery of anti-liver injury and disease: recent updates. Biomed Pharmacother. 2021;138:111507.
[7] Williamson EM, Liu X, Izzo AA. Synergy between herbal medicines and drugs: a systematic review of interactions. Phytother Res. 2020;34(4):896–917.
[8] Tang B, Ma L, Wang H, Zhang G, Sun F, Li Y. Solubility, stability and bioavailability enhancement strategies for curcumin: an updated review. J Nutr Food Sci. 2015;5(5):1000393.
[9] Allen TM, Cullis PR. Liposomal drug delivery systems: from concept to clinical applications. Adv Drug Deliv Rev. 2013;65(1):36–48.
[10] Ong ZY, Chin CF, Radosz M, Qiao S. Preservation of the asialoglycoprotein receptor-targeting functionality of galactosylated polymeric micelles upon freeze-drying. Biomaterials. 2010;31(8):1931–1939.
[11] Bombardelli E, Curri SB, Loggia RD, Tubaro A. Complexes between phospholipids and vegetal derivatives of biological interest. Fitoterapia. 1991;62(1):1–6.
[12] Kidd PM, Head K. A review of the bioavailability and clinical efficacy of milk thistle phytosome: a galactolipid delivery system for silymarin. Altern Med Rev. 2005;10(3):193–203.
[13] Kumar S, Alhassan M, Mohapatra B, Mondal S, Dhara AK, Singh SK. Polymeric nanoparticles for designing formulations with improved physicochemical properties and therapeutic benefits. Pharm Nanotechnol. 2019;7(3):167–179.
[14] Fong SY, Bong CW, Cham KA, Pung YF, Shekaran S, Tang YQ. Nanoencapsulation of andrographolide in PLGA to enhance therapeutic potential and limit toxicity: a preclinical study in hepatic cell lines. Int J Pharm. 2021;604:120746.
[15] Khan I, Saeed K, Khan I. Nanoparticles: properties, applications and toxicities. Arab J Chem. 2019;12(7):908–931.
[16] Kang MJ, Cho CW. Enhanced bioavailability of silymarin using a ground mixture with branched cyclodextrin. Pharmaceutics. 2020;12(6):576.
[17] Mehnert W, Mäder K. Solid lipid nanoparticles: production, characterization and applications. Adv Drug Deliv Rev. 2012;64(suppl):83–101.
[18] Gopi S, Jacob J, Varma K, Nampoothiri M. Curcumin nanoformulations: an emerging platform for improved health benefits. J Agric Food Chem. 2021;69(44):13001–13009.
[19] Calori IR, Braga G, Cavallini GS, Lancellotti M, Aparecido dos Santos G, Tavares ER. Polymeric

nanogels as versatile nanoplatforms for biomedical applications: an up-to-date overview. Eur Polym J. 2020;134:109844.
[20] Hussain Z, Thu HE, Amjad MW, Ahmed TA, Khan S. Exploring recent developments to improve antioxidant, anti-inflammatory and antimicrobial efficacy of curcumin: a review of new trends and future prospects. Mater Sci Eng C. 2019;77:1316–1326.
[21] Mura S, Nicolas J, Couvreur P. Stimuli-responsive nanocarriers for drug delivery. Nat Mater. 2013;12(11):991–1003.
[22] Fang J, Nakamura H, Maeda H. The EPR effect: unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. Adv Drug Deliv Rev. 2011;63(3):136–151.
[23] McClements DJ. Nanoparticle- and microparticle-based delivery systems: encapsulation, protection and release of active compounds. Boca Raton: CRC Press; 2014.
[24] Chime SA, Onyishi IV, Brown SA. Polymeric nanoparticles: a promising tool for drug delivery. Res J Pharm Tech. 2020;13(7):3330–3338.
[25] Spagnuolo R, Napolitano G, Tedesco I, Moccia S, Di Pierro P. Protective effect of silymarin against CCl4-induced acute liver damage in rats: histopathological and immunohistochemical analysis. Histol Histopathol. 2015;30(11):1395–1403.
[26] Suresh D, Srinivas K, Kumar S, Sharath B, Divya GN, Mohan IK. Effect of liposomal curcumin in preventing hepatic ischemia-reperfusion injury in rats: a comparative study with free curcumin. Transplant Proc. 2020;52(6):1824–1829.
[27] Kasdallah-Grissa A, Mornagui B, Aouani E, Hammami M, El-May M, Gharbi N. A pilot study on the efficacy of nanoformulated silymarin in alcoholic fatty liver disease. Alcohol. 2019;82:81–89.
[28] Cicero AF,etal., Phytosome curcumin in non-alcoholic fatty liver disease: a randomized placebo-controlled trial. Metab Syndr Relat Disord. 2021;19(3):128–133.
[29] Li B, Zhang K, Gao L, Yang Q, Li J, Qin S. Glycyrrhizin liposomes as a synergistic therapy for chronic hepatitis B. Int J Pharm. 2020;582:119335.
[30] Heinrich M. Quality and safety of herbal medical products: regulation and the need for quality assurance along the value chains. Br J Clin Pharmacol. 2015;80(1):62–66.
[31] Upton R, Graff A, Jolliffe G, Länger R, Williamson E. American Herbal Pharmacopoeia: botanical pharmacognosy: microscopic characterization of botanical medicines. CRC Press; 2011.
[32] Yang H. Nanoparticle-mediated immune modulation. J Mater Chem B. 2017;5(3):401–417.
[33] Astete CE, Sabliov CM. Synthesis and characterization of PLGA nanoparticles. J Biomater Sci Polym Ed. 2006;17(3):247–289.
[34] Lammers T, Kiessling F, Ashford M, Hennink W, Crommelin D, Storm G. Cancer nanomedicine: is targeting our target? Nat Rev Mater. 2016;1:16069.
[35] Faucitano A, Brecchia G, Dallagiacoma G, Preziosi R. Personalized herbal therapy: exploring the synergy between genomics and phytotherapy for the treatment of metabolic disorders. Curr Pharm Des. 2020;26(29):3596–3604.
[36] Tripathi A, Upadhyay S, Nara S. Future perspectives of artificial intelligence (AI) and machine learning (ML) in pharmaceutical sciences. J Pharm Biomed Anal. 2022;217:114833.
[37] Nasrollahzadeh M, Sajjadi M, Sajadi SM, Issaabadi Z, Varma RS. An overview on green nanomaterials for sustainable water purification. Chem Rec. 2019;19(6):1119–1131.
[38] Wais U, Vuddanda PR, Van Der Walle CF, Cronin M, Wilson CG. Nanocarriers for the treatment of oral cancer and other diseases of the oral cavity: an update on research and clinical translation. Pharmaceutics. 2021;13(9):1474.